Skip Main Navigation
Page Content
This event has ended

Save This Event

Event Saved

Conference on Cell & Gene Therapy for HIV Cure 2014


Tuesday, August 26, 2014 at 8:00 AM - Wednesday, August 27, 2014 at 3:00 PM (PDT)

Conference on Cell & Gene Therapy for HIV Cure 2014

Registration Information

Registration Type Sales End Price Fee Quantity
Early Bird Registration (ends July 7) Ended $450.00 $0.00
Registration (starts July 8) Ended $550.00 $0.00
TRAINEES/Post Docs and Grad students
Eligible Scientific Trainees can register at no charge for up to 2 sessions. You can also attend Keynote (which does not count against your 2 sessions, but you will need to select Keynote.)
Ended Free $0.00
8/26 MOHAI dinner guest
8/26 lakeside dinner is included in participant registration. Guest dinner tickets are available for an additional $50. For menu information:
Ended $50.00 $0.00

Event Details

defeatHIV, in collaboration with the Fred Hutchinson Cancer Research Center, the University of Washington Center for AIDS Research (CFAR) and the University of Washington Virology Division, will host the "Conference on Cell & Gene Therapy for HIV Cure” in Seattle on August 26-27 2014. The event will be held on the campus of the Fred Hutchinson Cancer Research Center.

Have questions about Conference on Cell & Gene Therapy for HIV Cure 2014? Contact defeatHIV

When & Where

Fred Hutchinson Cancer Research Center
1100 Fairview Avenue North
Pelton Auditorium
Seattle, WA 98109

Tuesday, August 26, 2014 at 8:00 AM - Wednesday, August 27, 2014 at 3:00 PM (PDT)

  Add to my calendar



defeatHIV, the Delaney Cell and Genome Engineering Initiative, is a consortium of committed investigators found in both academic and private sector research institutions, working together for a common purpose—to eradicate HIV.  As a Martin Delaney Collaboratory (MDC) program, we are inspired to re-examine existing approaches in the fight against AIDS and to focus our energies on developing innovative and novel strategies to abrogate the spread of this debilitating disease. Our core technologies utilize the latest cell and gene therapy approaches to eliminate latently-infected cells after viral reactivation, and improve the body’s ability to control unpredictable reactivation events from a therapeutically-reduced reservoir.  It is our mission to leverage the knowledge, expertise and resources of the consortium to generate a realistic and promising pathway toward the ultimate goal of an HIV cure.

  Contact the Organizer

Please log in or sign up

In order to purchase these tickets in installments, you'll need an Eventbrite account. Log in or sign up for a free account to continue.